Mladsi D, Ronquest N, Odom D, Miles L, Saag K. Cost-effectiveness of low-dose submicron diclofenac compared with generic diclofenac. Clin Ther. 2016 Nov;38(11):2418-29. doi: 10.1016/j.clinthera.2016.09.013
Mladsi DM, Ronquest NA, Tannus G, Fonseca M, Saag K. Estimated cost effectiveness of lower-dose submicron diclofenac compared with traditional diclofenac in Brazil. Poster presented at the 2013 ISPOR 4th Latin America Conference; September 2013. Buenos Aires, Argentina. [abstract] Value Health. 2013 Sep; 16(7):PA717-8. doi: 10.1016/j.jval.2013.08.2226
Hauber AB, Fleischmann J, Lothgren M, Wilson M, Lam A, Dubois D, Sabatowski R. Economic evaluation of OROS hydromorphone for chronic pain: a Pan-European perspective. J Opioid Manag. 2011 Jul 1;7(4):287-96.
Davis KL, Mitra D, Medjedovic J, Beam C, Rustgi V. Direct economic burden of chronic hepatitis c virus in a United States managed care population. J Clin Gastroenterol. 2011 Feb 1;45(2):e17-24.
Earnshaw SR, Wilson MR, Dalal AA, Chambers MG, Jhingran P, Stanford R, Mapel DW. Cost-effectiveness of fluticasone propionate/salmeterol (500/50 microg) in the treatment of COPD. Respir Med. 2009 Jan 1;103(1):12-21.
Hauber AB, Lam A, Fleishmann J, Wilson MR. European economic evaluation of OROS hydromorphone in the management of severe chronic cancer and non-cancer pain. Poster presented at the 2008 ISPOR 11th Annual European Congress; November 2008. Athens, Greece. [abstract] Value Health. 2008 Nov; 11(6):A640.
Candrilli SD, Iyer S, Davis KL. Impact of constipation on health care utilization and costs in patients on opioid therapy. Poster presented at the 2007 ISPOR 10th Annual European Congress; October 2007. Dublin, Ireland.
Davis KL, Candrilli SD, Iyer S. Impact of constipation on resource utilization and costs in non-metastatic cancer patients on opioid therapy. Poster presented at the Annual Clinical Meeting of the American Academy of Pain Management; September 2007.
Lehmann K, Radbruch L, Gockel HH, Neighbors D, Nuyts G. Costs of opioid therapy for chronic nonmalignant pain in Germany: an economic model comparing transdermal fentanyl (Duragesic) with controlled release morphine. Eur J Health Econ. 2002;3:111-9. doi: 10.1007/s10198-002-0097-6.
Neighbors DM, Dodd SL. Re: economic evaluation of fentanyl - Response. J Pain Symptom Manage. 2001 Jan 1;22(1):541-3.
Neighbors DM, Lopez R, Ingham M, Bell TJ. A Canadian adaptation of a decision analytic model for the economic evaluation of opioids for chronic pain. Poster presented at the 2000 ISPOR 3rd Annual European Congress; November 2000. Antwerp, Belgium.
Neighbors DM, Bell T, Wilson TJ, Dodd SL. A three-phased decision analytic model for the economic evaluation of opioid therapy for chronic pain. Poster presented at the 1999 ISPOR 4th Annual International Meeting; May 1999. Arlington, VA.